Rojas M P, Telaro E, Russo A, Fossati R, Confalonieri C, Liberati A
Department of Clinical Oncology Research, Mario Negri Institute, Via Eritrea 62, Milano, Italy.
Cochrane Database Syst Rev. 2000(4):CD001768. doi: 10.1002/14651858.CD001768.
Follow-up examinations are commonly performed after primary treatment for women with breast cancer. They are used to detect recurrences at an early (asymptomatic) stage.
To assess the effectiveness of different policies of follow-up for distant metastases on mortality, morbidity and quality of life in women treated for early breast cancer.
We searched the Breast Cancer Groups specialised register, the Cochrane Controlled Trials Register ( Cochrane Library Issue 4, 1999), MEDLINE (January 1975-September 1999) and EMBASE (1988-September 1999) using "Breast Neoplasms" and "follow-up". References from retrieved articles were also checked, as were the lists of presentations from recent breast cancer meetings.
All randomised controlled trials (RCTs) assessing the effectiveness of different policies of follow-up after primary treatment were reviewed for inclusion.
Two reviewers independently assessed trial quality and eligibility for inclusion in the review. Data were pooled in an individual patient data meta-analysis for the two RCTs testing the effectiveness of different follow-up schemes. Subgroup analyses by age, tumour size and lymph node status before primary treatment are also presented.
Four RCTs involving 3204 women with early breast cancer (clinical stage I, II or III) have been included. Two RCTs involving 2563 women compared follow-up based on clinical visits and mammography with a more intensive scheme including radiological and laboratory tests. After pooling the data, no significant differences in overall survival (hazard ratio 0.96, 95% confidence interval 0.80 to 1.15) or disease-free survival (hazard ratio 0.84, 95% confidence interval 0.71 to 1.00) emerged. No differences in overall survival and disease-free survival emerged in subgroup analyses according to patient age, tumour size and lymph node status before primary treatment. One RCT (296 women) compared follow-up performed by a hospital-based specialist to follow-up performed by general practitioners. No significant differences in time to detection of recurrence and quality of life emerged. One RCT (196 women) compared regularly scheduled follow-up visits to less frequent visits restricted to the time of mammography. No significant differences emerged in interim use of telephone and frequency of GP's consultations.
REVIEWER'S CONCLUSIONS: Follow-up programs based on regular physical examinations and yearly mammography alone appear to be as effective as more intensive approaches based on regular performance of laboratory and instrumental tests in terms of timeliness of recurrence detection, overall survival and quality of life. In one RCT, follow up care performed by general practitioners had comparable effectiveness to that delivered by hospital based specialists in terms of quality of life and time to detection of distant metastases.
乳腺癌女性患者在接受初始治疗后通常要进行随访检查,用于在早期(无症状)阶段检测复发情况。
评估针对远处转移的不同随访策略对早期乳腺癌女性患者死亡率、发病率及生活质量的有效性。
我们检索了乳腺癌专题注册库、Cochrane对照试验注册库(《Cochrane图书馆》1999年第4期)、MEDLINE(1975年1月至1999年9月)以及EMBASE(1988年至1999年9月),检索词为“乳腺肿瘤”和“随访”。对检索到的文章的参考文献以及近期乳腺癌会议的报告列表也进行了检查。
对所有评估初始治疗后不同随访策略有效性的随机对照试验(RCT)进行审查以确定是否纳入。
两名评价员独立评估试验质量及纳入本综述的资格。对两项测试不同随访方案有效性的RCT进行个体患者数据荟萃分析以汇总数据。还给出了根据年龄、肿瘤大小及初始治疗前淋巴结状态进行的亚组分析。
纳入了四项涉及3204例早期乳腺癌(临床I期、II期或III期)女性患者的RCT。两项涉及2563例女性患者的RCT比较了基于临床检查和乳房X线摄影的随访与包括放射学和实验室检查在内的更强化方案的随访。汇总数据后,总生存(风险比0.96,95%置信区间0.80至1.15)或无病生存(风险比0.84,95%置信区间0.71至1.00)方面未出现显著差异。根据患者年龄、肿瘤大小及初始治疗前淋巴结状态进行的亚组分析中,总生存和无病生存方面也未出现差异。一项RCT(296例女性患者)比较了由医院专科医生进行的随访与由全科医生进行的随访。在复发检测时间和生活质量方面未出现显著差异。一项RCT(196例女性患者)比较了定期安排的随访就诊与仅限于乳房X线摄影时的较少频次就诊。在电话的临时使用和全科医生会诊频率方面未出现显著差异。
就复发检测的及时性、总生存和生活质量而言,仅基于定期体格检查和年度乳房X线摄影的随访方案似乎与基于定期进行实验室和器械检查的更强化方法一样有效。在一项RCT中,就生活质量和远处转移检测时间而言,全科医生提供的后续护理与医院专科医生提供的后续护理效果相当。